Shares of Lupin Ltd surged 2.38 per cent to ₹2,364.65 on the BSE at 11.27 AM and it reached an all-time high of ₹2,372.55 during the session.
Lupin Ltd., a global pharmaceutical company, announced on December 30, the acquisition of the Huminsulin range of products in India from Eli Lilly and Company. The financial terms of the deal were not disclosed.
This strategic acquisition would significantly strengthen Lupin’s position in the Indian diabetes market. The company has been marketing the Huminsulin range, including Huminsulin R, Huminsulin NPH, Huminsulin 50/50, and Huminsulin 30/70, through existing agreements with Eli Lilly India.
The Huminsulin range is a treatment option for both type 1 and type 2 diabetes, helping to regulate blood sugar levels in adults and children.
“This acquisition aligns perfectly with our ongoing commitment to expanding our diabetes portfolio and providing high-quality, affordable healthcare solutions to patients across India,” said Nilesh Gupta, Managing Director of Lupin.
Rajeev Sibal, President (India Region Formulations) at Lupin, emphasized that this acquisition enables the company to offer a comprehensive range of human insulin options to patients, further enhancing their access to vital medications.
Emkay analysts have maintained a “buy” rating on Lupin with a target price of ₹2,750 per share citing that, Teva’s petition for an en banc rehearing in the gProAir litigation suggests a potential delay in Amneal’s launch of the generic drug. This is seen as a positive for Lupin, as it could slow down the decline of gProAir sales.
According to analyst report, Amphastar, another player in the Albuterol market, has been facing capacity constraints and expects a gradual ramp-up in its market share. This also supports a slower decline in gProAir sales for Lupin.
Furthermore, consensus estimates for Lupin’s FY26 EPS have been upgraded by ~13 per cent in the last 3 months. Further upgrades were expected, as the company’s medium-term margin guidance of 23-25 per cent was considered conservative.
Lupin is currently trading at ~24x FY26E EPS, in line with its 5-year average trading range.
